Abstract
Adiponectin, a newly discovered adipose-tissue secreting hormone, is a major regulator of a wide spectrum of physiological processes, such as energy metabolism, inflammation and vascular homeostasis. Emerging data suggest that adiponectin is the link between obesity and obesity-related disorders with cardiovascular disease. Adiponectin is a dominant insulin-sensitive adipokine and, in contrast to other adipose-tissue derived cytokines, it has major anti-diabetic, antiatherogenic and anti-inflammatory properties. Adiponectin has been extensively studied in the context of several aspects and risk factors of cardiovascular disease such as obesity, diabetes type I and II, coronary heart disease, hypertension, heart failure, cerebrovascular disease and smoking. The aim of this article is to summarize the acquired so far knowledge on adiponectin in relation to cardiovascular disease, to review its main biological and biochemical characteristics, to highlight the main mechanisms of adiponectin-driven beneficial effects on vasculature and briefly to refer to the basic correlations of adiponectin with the important aforementioned aspects of cardiovascular disease.
Keywords: Adiponectin, biomarker, cardiovascular disease, coronary artery disease, diabetes mellitus, heart failure, hypertension, obesity, metabolic syndrome
Current Topics in Medicinal Chemistry
Title:Adiponectin: Merely a Bystander or the Missing Link to Cardiovascular Disease?
Volume: 13 Issue: 2
Author(s): Georgios Hatzis, Spyridon Deftereos, Dimitris Tousoulis, Georgios Bouras, Georgios Giannopoulos, Nikolaos Anatoliotakis, Dimitrios Tsounis and Christodoulos Stefanadis
Affiliation:
Keywords: Adiponectin, biomarker, cardiovascular disease, coronary artery disease, diabetes mellitus, heart failure, hypertension, obesity, metabolic syndrome
Abstract: Adiponectin, a newly discovered adipose-tissue secreting hormone, is a major regulator of a wide spectrum of physiological processes, such as energy metabolism, inflammation and vascular homeostasis. Emerging data suggest that adiponectin is the link between obesity and obesity-related disorders with cardiovascular disease. Adiponectin is a dominant insulin-sensitive adipokine and, in contrast to other adipose-tissue derived cytokines, it has major anti-diabetic, antiatherogenic and anti-inflammatory properties. Adiponectin has been extensively studied in the context of several aspects and risk factors of cardiovascular disease such as obesity, diabetes type I and II, coronary heart disease, hypertension, heart failure, cerebrovascular disease and smoking. The aim of this article is to summarize the acquired so far knowledge on adiponectin in relation to cardiovascular disease, to review its main biological and biochemical characteristics, to highlight the main mechanisms of adiponectin-driven beneficial effects on vasculature and briefly to refer to the basic correlations of adiponectin with the important aforementioned aspects of cardiovascular disease.
Export Options
About this article
Cite this article as:
Hatzis Georgios, Deftereos Spyridon, Tousoulis Dimitris, Bouras Georgios, Giannopoulos Georgios, Anatoliotakis Nikolaos, Tsounis Dimitrios and Stefanadis Christodoulos, Adiponectin: Merely a Bystander or the Missing Link to Cardiovascular Disease?, Current Topics in Medicinal Chemistry 2013; 13 (2) . https://dx.doi.org/10.2174/1568026611313020005
DOI https://dx.doi.org/10.2174/1568026611313020005 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Endothelial Lipase: A Key Player in HDL Metabolism Modulates Inflammation and Atherosclerotic Risk
Mini-Reviews in Medicinal Chemistry Curcumin Nanomicelle Improves Lipid Profile, Stress Oxidative Factors and Inflammatory Markers in Patients Undergoing Coronary Elective Angioplasty; A Randomized Clinical Trial
Endocrine, Metabolic & Immune Disorders - Drug Targets Salt: A Review of its Role in Food Science and Public Health
Current Nutrition & Food Science Potassium Channel Openers and Improvement of Toxic Stress: Do they have Role in the Management of Inflammatory Bowel Disease?
Inflammation & Allergy - Drug Targets (Discontinued) Myocardial Regeneration: What is the Best Approach?
Current Cardiology Reviews Why Multiples of 21? Why does Selenoprotein P Contain Multiple Selenocysteine Residues?
Current Nutraceuticals Non-Lipid Effects of Statins: Emerging New Indications
Current Vascular Pharmacology Pre-Emptive Conditioning of the Ischemic Heart
Cardiovascular & Hematological Agents in Medicinal Chemistry Chips for Brains
Current Genomics Neuroprotective Mechanisms of Oxygen and Ethanol: A Potential Combination Therapy in Stroke
Current Medicinal Chemistry Troponin in Newborns and Pediatric Patients
Cardiovascular & Hematological Agents in Medicinal Chemistry Nanocarriers for Tracking and Treating Diseases
Current Medicinal Chemistry Malignancy and Radiation-Induced Cardiotoxicity
Cardiovascular & Hematological Disorders-Drug Targets Non Invasive Imaging of Myocardial Infarction with Computed Tomography and Magnetic Resonance
Current Vascular Pharmacology Alkaloids as Important Scaffolds in Therapeutic Drugs for the Treatments of Cancer, Tuberculosis, and Smoking Cessation
Current Topics in Medicinal Chemistry Novel Anti-Platelets in Stable Coronary Artery Disease
Current Pharmaceutical Design Therapeutic Modulation of Glutamate Receptors in Major Depressive Disorder
Current Neuropharmacology Natural Bioactives as Potential Therapeutic Modalities Against NeuroAIDS
Current Topics in Medicinal Chemistry Vasoactive Compounds in the Neonatal Period
Current Medicinal Chemistry Anti-Interleukin-6 Receptor Antibody Therapy in Rheumatic Diseases
Endocrine, Metabolic & Immune Disorders - Drug Targets